You are here

Article Text

Article menu
Download PDFPDF
Mutation report
NARP syndrome in a patient harbouring an insertion in the MT-ATP6 gene that results in a truncated protein
  1. E López-Gallardo1,2,3,
  2. A Solano1,
  3. M D Herrero-Martín1,2,3,
  4. Í Martínez-Romero1,2,3,
  5. M D Castaño-Pérez4,
  6. A L Andreu2,5,
  7. A Herrera6,
  8. M J López-Pérez1,2,3,
  9. E Ruiz-Pesini1,2,3,7,
  10. J Montoya1,2,3
  1. 1
    Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, 50013-Zaragoza, Spain
  2. 2
    CIBER de Enfermedades Raras (CIBERER), ISCIII, Spain
  3. 3
    Instituto Aragonés de Ciencias de la Salud, Spain
  4. 4
    Servicio de Neurología. Hospital Virgen de los Lirios, Alcoy, Alicante, Spain
  5. 5
    Hospital Vall d’Hebron, Barcelona, Spain
  6. 6
    Servicio de Cirugía Ortopédica y Traumatología, Hospital Miguel Servet, Zaragoza, Spain
  7. 7
    Fundación Aragón I+D (ARAID), Spain
  1. Professor J Montoya. Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Miguel Servet 177, 50013-Zaragoza, Spain; jmontoya{at}unizar.es

Abstract

Background: Neurogenic muscle weakness, ataxia and retinitis pigmentosa (NARP) syndrome have been associated to m.8993T>G/C mutations in the subunit 6 of the ATP synthase (p.MT-ATP6).

Methods: We have performed a mutational screening of the mitochondrial DNA gene encoding for this protein in 62 patients with the disease, that do not carry any of the common mutations described to date.

Results: We report clinical and molecular data in one patient who harbours a de novo insertion in the MT-ATP6 gene that results in a truncated subunit. The mutation was heteroplasmic (85%) in muscle DNA and the BN-PAGE analysis showed a clear decrease in the amount of ATP synthase.

Conclusion: Molecular analysis of NARP patients cannot be limited to the search of the m.8993T>G/C and either the ATP6 or the whole mtDNA should be sequenced.

https://doi.org/10.1136/jmg.2008.060616

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding: This project was supported by grants from Instituto de Salud Carlos III-FIS (PI07-0045, PI07/90512), Diputación General de Aragón (Grupos Consolidados B33). MDH-M and IM-R are supported by a predoctoral fellowships FIS (FI05/00501 and FI0700184). The CIBER de Enfermedades Raras is an initiative of the ISCIII.

    • Competing interests: None.

    • Patient consent: Obtained.

    • AS present address: Centro de Investigación Príncipe Felipe, Valencia, Spain